Immunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. Its lead development program is IMU-838, which is in Phase 2 clinical for treatment of relapsing-remitting multiple sclerosis, inflammatory bowel disease, and other chronic inflammatory and autoimmune diseases, as well as to treat coronavirus disease. The company is also developing IMU-935, an inverse agonist of ROR?t; and IMU-856 for the restoration of the intestinal barrier function in patients suffering from diseases, such as inflammatory bowel disease, irritable bowel syndrome with diarrhea, immune checkpoint inhibitor induced colitis, and other intestinal barrier function diseases. Immunic, Inc. is headquartered in New York, New York.
IPO Year: 2014
Exchange: NASDAQ
Website: immunic-therapeutics.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/9/2024 | $5.00 | Outperform | Leerink Partners |
| 8/27/2024 | $6.00 | Buy | B. Riley Securities |
| 10/21/2022 | $5.00 | Outperform → Mkt Perform | SVB Leerink |
| 9/19/2022 | $26.00 | Buy | H.C. Wainwright |
| 9/7/2021 | $40.00 → $25.00 | Buy | HC Wainwright & Co. |
– Senior Executive and Thought Leader in Brain Health with Nearly Three Decades of Global Pharmaceutical Experience – – Served as Neuroimmunology Franchise Head Responsible for Roche's Blockbuster Launch of Multiple Sclerosis Therapy Ocrevus® – NEW YORK, July 24, 2024 /PRNewswire/ -- Immunic, Inc. (NASDAQ:IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced the appointment of Simona Skerjanec, M.Pharm, MBA, a thought-leader in brain health with decades of experience in drug development and commercialization, to its board of directors, effective July 22, 2024. Over a nea
– Former Novartis and Biogen Executive Brings Extensive Multiple Sclerosis Drug Commercialization Experience to Immunic – – Werner Gladdines, Current Vice President, Program Management & Clinical Development Operations, Promoted to Chief Development Officer – NEW YORK, July 9, 2024 /PRNewswire/ -- Immunic, Inc. (NASDAQ:IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced that seasoned biopharmaceutical executive, Jason Tardio, will be joining the company as Chief Operating Officer and President, effective July 12, 2024. In the newly created role, Mr. Tardio will lead in
– Thought-Leader in Multiple Sclerosis with Decades of Experience in Academic Medicine and the Pharmaceutical Industry – NEW YORK, April 27, 2023 /PRNewswire/ -- Immunic, Inc. (NASDAQ:IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced the appointment of Richard Rudick, M.D., a thought-leader in multiple sclerosis with decades of experience in the clinic, academia and industry, to its board of directors, effective April 26, 2023. The company also announced that Vincent Ossipow, Ph.D., will step down from the Board, effective June 28, 2023. "We are very grateful to have
– Global Commercial Executive Brings 20 Years of Sales and Marketing Expertise –– Jan Van den Bossche Steps Down from Board After Six Year Tenure – NEW YORK , July 6, 2022 /PRNewswire/ -- Immunic, Inc. (NASDAQ:IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, today announced the appointment of Maria Törnsén, an industry executive with 20 years of global commercial experience in U.S. and ex-U.S. markets, to its Board of Directors, effective July 5, 2022. The company also announced that Jan Van den Bossche has stepped down from the Board, effective July 5, 2022. "Maria
NEW YORK, Oct. 14, 2021 /PRNewswire/ -- Immunic, Inc. (NASDAQ:IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, announced the appointment of Patrick Walsh as Chief Business Officer, effective today. In this newly created role, Mr. Walsh will be responsible for business development, including strategic partnering opportunities, and will become part of the executive management team of Immunic. "Patrick is a seasoned business development executive who has spent his career helping to successfully build a number of public biopharmaceutical companies. He brings to Immunic
NEW YORK, June 1, 2021 /PRNewswire/ -- Immunic, Inc. (NASDAQ:IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, announced the appointment of Inderpal Singh as General Counsel, effective today. In his new role, Mr. Singh will be responsible for legal and compliance matters and will become part of the management team of Immunic. "Inderpal is a seasoned legal executive, having spent 20 years in-house, advising several of the world's largest life sciences companies. As such, he brings to Immunic extensive legal knowledge related to clinical development, operations, regulato
Piper Sandler analyst Yasmeen Rahimi reiterates Immunic (NASDAQ:IMUX) with a Overweight and maintains $28 price target.
The company also reported that Werner Gladdines, current Vice President, Program Management & Clinical Development Operations, has been promoted to Chief Development Officer.
https://www.sec.gov/Archives/edgar/data/1280776/000119380524000704/e663650_s3a-immunic.htm
Immunic (NASDAQ:IMUX) reported quarterly losses of $(0.30) per share which missed the analyst consensus estimate of $(0.26) by 15.38 percent. This is a 48.28 percent increase over losses of $(0.58) per share from the same period last year.
30 mg and 45 mg Daily Doses of Vidofludimus Calcium Suppressed Development of Gadolinium-Enhancing Lesions by 78% and 74% Compared to Pooled Placebo at 24 Weeks. Improvements in Serum Neurofilament Light Chain Consistent with Recently Announced Interim Phase 2 CALLIPER Data in Progressive Multiple Sclerosis. Twin Phase 3 ENSURE Trials in Relapsing Multiple Sclerosis and Phase 2 CALLIPER Trial in Progressive Multiple Sclerosis Remain Underway.
Brookline Capital analyst Tyler Bussian initiates coverage on Immunic (NASDAQ:IMUX) with a Buy rating and announces Price Target of $10.
The Dow Jones index closed lower by over 20 points on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision. Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform. OPKO Health The Trade: OPKO Health, Inc. (NASDAQ:OPK) 10% owner Frost Gamma Investments Trust acquired a total of 500,000 shares an average price of $0.99. To acquire these shares, it cost around $496,150. What’s Happening: On Feb. 27, OPKO Hea
4 - IMMUNIC, INC. (0001280776) (Issuer)
4 - IMMUNIC, INC. (0001280776) (Issuer)
3 - IMMUNIC, INC. (0001280776) (Issuer)
4 - IMMUNIC, INC. (0001280776) (Issuer)
3 - IMMUNIC, INC. (0001280776) (Issuer)
4 - IMMUNIC, INC. (0001280776) (Issuer)
4 - IMMUNIC, INC. (0001280776) (Issuer)
4 - IMMUNIC, INC. (0001280776) (Issuer)
4 - IMMUNIC, INC. (0001280776) (Issuer)
4 - IMMUNIC, INC. (0001280776) (Issuer)
4 - IMMUNIC, INC. (0001280776) (Issuer)
4 - IMMUNIC, INC. (0001280776) (Issuer)
– 24-Week Data from First Half of Patients Shows Improvements in Biomarker NfL, Consistent Throughout the Overall Progressive Multiple Sclerosis Population as well as All Subtypes – – NfL Effect in Non-Active Subpopulation Reinforces Vidofludimus Calcium's Neuroprotective Potential – – Brain Volume Data of the Full 467 CALLIPER Patient Cohort Expected in April 2025 – – Phase 3 ENSURE Program in Relapsing Multiple Sclerosis Ongoing – – Conference Call and Webcast to be Held Tomorrow, October 10, 2023 at 8:00 am ET – NEW YORK, Oct. 9, 2023 /PRNewswire/ -- Immunic, Inc. (NASDAQ:IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chr
– Positive Effects Demonstrated Over Placebo in Four Key Dimensions of Celiac Disease Pathophysiology: Protection of Gut Architecture, Improvement of Patients' Symptoms, Biomarker Response, and Enhancement of Nutrient Absorption – – Corroborates Hypothesized Ability of IMU-856 to Renew Gut Wall and Restore Gut Health – – No Safety or Tolerability Issues Detected – – Conference Call and Webcast to be Held Today, May 4, 2023 at 8:00 am ET – NEW YORK, May 4, 2023 /PRNewswire/ -- Immunic, Inc. (NASDAQ:IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced positive results fro
– 50-Week Maintenance Phase Data Shows Dose-Linear Increase in Clinical Remission for Vidofludimus Calcium as Compared to Placebo – – 30 mg Once-Daily Dose of Vidofludimus Calcium Demonstrated Statistically Significant Rates of Clinical Remission (p=0.0358) and Endoscopic Healing (p=0.0259) at Week 50 – – To Focus Resources on High Performing Vidofludimus Calcium and IMU-856 Programs, Immunic Decided to Deprioritize Izumerogant (IMU-935) Program – – Conference Call and Webcast to be Held today, April 5, 2023 at 8:00 am ET – NEW YORK, April 5, 2023 /PRNewswire/ -- Immunic, Inc. (NASDAQ:IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapi
– Conference Call and Webcast to be Held Today, February 9, 2023, at 11:00 am ET – NEW YORK, Feb. 9, 2023 /PRNewswire/ -- Immunic, Inc. (NASDAQ:IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, announced that its Celiac Disease R&D Webcast will take place today, February 9, 2023 from 11:00 am to 1:00 pm ET. Management of Immunic, including Daniel Vitt, Ph.D., Chief Executive Officer and President; Andreas Muehler, M.D., M.B.A., Chief Medical Officer; and Hella Kohlhof, Ph.D., Chief Scientific Officer, will be joined by renowned key opinion leaders to discuss the dyna
– Trial Did Not Achieve Primary Endpoint in the Ulcerative Colitis (UC) Population Caused by Unexpected Interference Between Vidofludimus Calcium and Concurrent Use of Corticosteroids – – In UC Population Without Concurrent Steroid Use, Pooled Vidofludimus Calcium Data Suggest Activity in Clinical Remission Over Placebo; Counterbalanced by Interference Observed in the UC Population with Concurrent Steroid Use – – Company Does Not Plan Further Development Activities in Ulcerative Colitis Without a Partner – – Focus to Remain on Ongoing Phase 3 Development of Vidofludimus Calcium in Multiple Sclerosis, and Ongoing IMU-935 and IMU-856 Programs with Clinical Data for Both Expected in 2022 – – $9
SC 13G/A - IMMUNIC, INC. (0001280776) (Subject)
SC 13G/A - IMMUNIC, INC. (0001280776) (Subject)
SC 13G/A - IMMUNIC, INC. (0001280776) (Subject)
SC 13G/A - IMMUNIC, INC. (0001280776) (Subject)
SC 13G - IMMUNIC, INC. (0001280776) (Subject)
SC 13G/A - IMMUNIC, INC. (0001280776) (Subject)
SC 13G/A - IMMUNIC, INC. (0001280776) (Subject)
SC 13G/A - IMMUNIC, INC. (0001280776) (Subject)
SC 13G/A - IMMUNIC, INC. (0001280776) (Subject)
SC 13G - IMMUNIC, INC. (0001280776) (Subject)
– Includes Phase 1 Data in Healthy Human Subjects and Phase 1b Data in Celiac Disease Patients – NEW YORK, Nov. 13, 2024 /PRNewswire/ -- Immunic, Inc. (NASDAQ:IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced that the data from its phase 1/1b clinical trial of IMU-856, an orally available and systemically acting small molecule modulator that targets SIRT6 (Sirtuin 6), has been published in the peer reviewed journal, The Lancet Gastroenterology & Hepatology. Lead authored by Dr. A. James Daveson, Gastroenterologist, Wesley Research Institute and Coral Sea Clinical Res
– Positive Interim Analysis of Phase 3 ENSURE Program, Unblinded Independent Data Monitoring Committee Confirmed that Predetermined Futility Criteria Have Not Been Met and Recommended Trials Should Continue as Planned – – Ongoing, Twin Phase 3 ENSURE Trials in Relapsing Multiple Sclerosis and Phase 2 CALLIPER Trial in Progressive Multiple Sclerosis Remain on Track – – Top-Line Data from Phase 2 CALLIPER Trial Expected in April 2025 – – Webcast to be Held Today, November 7, at 8:00 am ET – NEW YORK, Nov. 7, 2024 /PRNewswire/ -- Immunic, Inc. (NASDAQ:IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoi
– Webcast to be Held at 8:00 am ET on November 7, 2024 – NEW YORK, Oct. 31, 2024 /PRNewswire/ -- Immunic, Inc. (NASDAQ:IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced that the company will release its financial results for the third quarter ended September 30, 2024, including a corporate update, on Thursday, November 7, 2024, before the opening of the U.S. financial markets. A webcast will follow at 8:00 am ET. To participate in the webcast, please register in advance at: https://imux.zoom.us/webinar/register/WN_v2_K1Ze-QKS34X6c9W9ywg or on the "Events and Presenta
NEW YORK, Oct. 29, 2024 /PRNewswire/ -- Immunic, Inc. (NASDAQ:IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced participation in the following industry, scientific and investor conferences in November: November 4-6: BIO-Europe. Members of Immunic's management, business development and investor relations teams will participate in partnering activities at this conference in Stockholm, Sweden. To schedule a meeting, please use the BIO-Europe partneringONE portal.November 8-9: Symposium 238: Immuno-Mediated Diseases of the GI Tract: Where Do We Stand? Sara Elhag, Ph.D.,
– Based on a Review of Unblinded Data, an Independent Data Monitoring Committee (IDMC) Confirmed that Predetermined Futility Criteria Have Not Been Met – – IDMC Also Recommended Continuing Trial without Changes, Including no Need for a Potential Upsizing – – ENSURE Program Remains on Track to be Completed in 2026 – – Webcast to be Held Today, October 22, at 8:00 am ET – NEW YORK, Oct. 22, 2024 /PRNewswire/ -- Immunic, Inc. (NASDAQ:IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced a positive outcome of the non-binding, interim futility analysis of its phase 3 ENSURE p
– Vidofludimus Calcium Consistently Reduced Neurofilament Light Chain Levels, Compared to Placebo, in the Interim Analysis of the Phase 2 CALLIPER Trial, Across Age and Disability Levels at Baseline For All Progressive Multiple Sclerosis Subtypes – – Clinical Signal Shown for Vidofludimus Calcium on Post COVID Fatigue May Be Related to Epstein-Barr Virus Reactivation; Preventing This Reactivation May Contribute to Fatigue Reduction in Multiple Sclerosis Patients – – Preclinical Data Showed Improved Neuronal Survival, Likely Driven by Vidofludimus Calcium's Induction of Nurr1 Activation, as Demonstrated by Primary Target Gene Regulation – – In Preclinical Experiments, Vidofludimus Calcium Red
– Investigator Study Sponsored by Goethe University Frankfurt (Germany), Funded via a German Government Grant; Study Drug Vidofludimus Calcium Provided by Immunic – – In Addition to Post COVID Readouts, Study Designed to Deliver Important Data on the Activity of Vidofludimus Calcium Suppressing Epstein-Barr Virus Reactivation and Related Fatigue Symptoms; Third-Party Research Identified Epstein-Barr Virus Reactivation as Potential Cause for Post COVID Fatigue – – Severe Fatigue Also a Common and Debilitating Symptom for Multiple Sclerosis Patients with No Effective Therapies Available; Potential Read-Through to Immunic's Multiple Sclerosis Development Program – NEW YORK, Sept. 4, 2024 /PRNew
NEW YORK, Aug. 28, 2024 /PRNewswire/ -- Immunic, Inc. (NASDAQ:IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced that the company will host a Multiple Sclerosis (MS) Research and Development (R&D) Day and participate in the following scientific and investor conferences in September: September 10: Immunic's MS R&D Day. Management of Immunic, including Daniel Vitt, Ph.D., Chief Executive Officer; Jason Tardio, M.B.A., Chief Operating Officer and President; Andreas Muehler, M.D., M.B.A., Chief Medical Officer; and Hella Kohlhof, Ph.D., Chief Scientific Officer, will be j
– Jason Tardio, Experienced Multiple Sclerosis Drug Commercialization Executive, Formerly with Novartis and Biogen, Appointed Chief Operating Officer and President – – Strengthened Board of Directors with Appointment of Simona Skerjanec, Senior Pharmaceutical Executive and Thought Leader in Brain Health – – Ongoing, Twin Phase 3 ENSURE Trials in Relapsing Multiple Sclerosis and Phase 2 CALLIPER Trial in Progressive Multiple Sclerosis Remain on Track – – Webcast to be Held Today, August 8, at 8:00 am ET – NEW YORK, Aug. 8, 2024 /PRNewswire/ -- Immunic, Inc. (NASDAQ:IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflam
– Webcast to be Held at 8:00 am ET on August 8, 2024 – NEW YORK, Aug. 1, 2024 /PRNewswire/ -- Immunic, Inc. (NASDAQ:IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced that the company will release its financial results for the second quarter ended June 30, 2024, including a corporate update, on Thursday, August 8, 2024, before the opening of the U.S. financial markets. A webcast will follow at 8:00 am ET. To participate in the webcast, please register in advance at: https://imux.zoom.us/webinar/register/WN_ae1TwcxTQ9GTkRUmQSOgTA or on the "Events and Presentations" se
10-Q - IMMUNIC, INC. (0001280776) (Filer)
8-K - IMMUNIC, INC. (0001280776) (Filer)
8-K - IMMUNIC, INC. (0001280776) (Filer)
8-K - IMMUNIC, INC. (0001280776) (Filer)
8-K - IMMUNIC, INC. (0001280776) (Filer)
10-Q - IMMUNIC, INC. (0001280776) (Filer)
8-K - IMMUNIC, INC. (0001280776) (Filer)
8-K - IMMUNIC, INC. (0001280776) (Filer)
8-K - IMMUNIC, INC. (0001280776) (Filer)
S-8 - IMMUNIC, INC. (0001280776) (Filer)
Leerink Partners resumed coverage of Immunic with a rating of Outperform and set a new price target of $5.00
B. Riley Securities initiated coverage of Immunic with a rating of Buy and set a new price target of $6.00
SVB Leerink downgraded Immunic from Outperform to Mkt Perform and set a new price target of $5.00
H.C. Wainwright resumed coverage of Immunic with a rating of Buy and set a new price target of $26.00
HC Wainwright & Co. reiterated coverage of Immunic with a rating of Buy and set a new price target of $25.00 from $40.00 previously
Aegis Capital initiated coverage of Immunic with a rating of Buy and set a new price target of $55.00
JMP Securities initiated coverage of Immunic with a rating of Market Outperform and set a new price target of $55.00
SVB Leerink resumed coverage of Immunic with a rating of Buy and set a new price target of $45.00